The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients

The DBCG89D trial randomized high-risk early breast cancer patients to adjuvant CMF (cyclophosphamide, methotrexate and fluorouracil) or CEF (cyclophosphamide, epirubicin and fluorouracil). Prosigna assays were performed by researchers with no access to clinical data. Time to distant recurrence (DR)...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:NPJ Breast Cancer
Autors principals: Jensen, Maj-Britt, Lænkholm, Anne-Vibeke, Balslev, Eva, Buckingham, Wesley, Ferree, Sean, Glavicic, Vesna, Dupont Jensen, Jeanette, Søegaard Knoop, Ann, Mouridsen, Henning T., Nielsen, Dorte, Nielsen, Torsten O., Ejlertsen, Bent
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7044229/
https://ncbi.nlm.nih.gov/pubmed/32140564
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41523-020-0148-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars